The African Access Initiative (AAI) is a partnership of companies, governments, healthcare providers, and NGOs focused on sustainably expanding access to cancer medicines and technologies, improving healthcare infrastructure, and building clinical and R&D capacity in Africa.
Driven by Africa - for Africa - AAI’s innovative approach engages stakeholders across sectors to accelerate access to cancer treatment. Using data generated at the country-level by African hospitals and governments, AAI is expanding access to cancer medicines and technologies, strengthening healthcare infrastructure, and building clinical oncology and R&D capacity in Africa.
Partnering with Governments
BVGH works with African Ministries of Health to align AAI with each country’s cancer priorities.
BVGH meets with Honorable André Mama Fouda, Minister of Health.
National Cancer Control Coordinator, Professor Innocent Adoubi, speaks at AAI symposium.
Dr. Anne Ng’ang’a, Head of Kenya’s National Cancer Control Program, presents Kenya’s cancer strategy at AAI launch.
AAI and AC3T presented alongside Professor Isaac Adewole, Minister of Health, at launch of Nigeria’s National Cancer Control Plan.
First Lady Jeannette Kagame and Dr. Diane Gashumba, Minister of Health, discuss AAI with Pfizer and BVGH.
AAI at the Biden Cancer Summit
Cancer in Africa is almost always fatal. It is time to change that. BVGH was invited to present AAI at the Biden Cancer Summit, hosted by VP Joe Biden and Dr. Jill Biden, and share our commitment to quadrupling the rate of progress against cancer in Africa.
Drug access agreement underway in Nigeria
Following a “Stakeholder Meeting on Cancer Drug Access and Harmonized Treatment Guidelines,” the Nigerian Minister of Health, Professor Isaac Adewole, and BVGH invited CEOs of leading pharmaceutical companies to submit proposals to make critical cancer drugs available in Nigeria. Twenty-four drugs targeting five prioritized cancers – breast, cervical, colorectal, liver, and prostate – are included. BVGH and the Ministry plan to execute agreements and treat the first patients in early 2019.
Learn more about the access program.
Capacity building in action
Six MSD* scientists participating in the MSD Fellowship for Global Health traveled to two AAI hospitals to volunteer for BVGH and build cancer clinical trial and diagnostic laboratory capacity. Throughout their fellowship, the fellows worked with physicians and hospital administrators at Moi Teaching and Referral Hospital in Kenya and the University Teaching Hospital of Kigali (CHUK) in Rwanda to transfer knowledge and skills to improve cancer patient care in the region.
Learn more about the MSD Fellowship for Global Health.
*MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.
AC³T: Access through Clinical Trials
Under the purview of AAI, BVGH launched the African Consortium for Cancer Clinical Trials (AC³T) to foster and implement cancer clinical trials led by investigators in Africa. AC³T is designed to build clinical trial capacity and address the cancer data gap in Africa while increasing access to prioritized cancer diagnostics, medicines, and quality treatment for African patients.
Learn more about AC³T.
Newsletters and Publications
- BVGH's African Access Initiative Featured at Biden Cancer Summit
- Nigerian Federal Ministry of Health to Launch Pilot Cancer Drug Access Program with BVGH
- International Drug Companies Join BVGH to Tackle Cancer Crisis in Africa
- Breast Cancer More Aggressive, Deadlier in African Women Than Caucasian Women
- Cancer Crisis in Africa Prompts BVGH's New African Access Initiative
Driven by Africa - for Africa
To learn more about the African Access Initiative, contact Katy Graef
Read our white paper,"Africa's Emerging Cancer Crisis: A Call to Action"
Check out global oncology resources